This list includes selected products resulting from research funded by CDMRP.
Clicking on the link will take you to the project's Abstract.
Breast Cancer Research Program
- Dr. Michael Wigler, Cold Spring Harbor Laboratory: Discovery of PTEN, a frequently mutated gene in several cancers as well as syndromes characterized by tumor growth, enabled development of a genetic test used for clinical and prenatal diagnoses.
- Dr. Eldon Jupe, University of Oklahoma: Risk association studies led to development of OncoVue®, a breast cancer risk assessment test that is commercially available and offered at over 30 breast care centers in the U.S.
- Dr. Mary Daly, Fox Chase Cancer Center: Developed the first resource book providing information for women considering prophylactic oophorectomy for ovarian cancer prevention and established a high-risk familial breast cancer registry that led to a family risk assessment program.
- Dr. Mina Bissell, Lawrence Berkeley National Laboratory: Development of 3D culture systems contributed to understanding the complexity of the tumor microenvironment and led to the development of screening assays to test for responses to drug treatments.
- Dr. Michelle Pagano, New York University: The Skp2 oncogene, which is overexpressed in breast tumors and correlates with poor prognosis, is part of a prognostic test performed in clinical pathology laboratories.
- Dr. Gregory Hannon, Cold Spring Harbor Laboratory and Dr. Stephen Elledge, Brigham and Women's Hospital: Expression Arrest™ shRNA libraries - Development of Expression Arrest™ shRNA libraries, targeting over 30,000 genes in the human and mouse genomes, provide rapid screening tests to study gene regulation and to identify new therapeutic targets.
- Dr. Laura Esserman, University of California, San Francisco: BreastCancerTrials.org is an online resource that provides information to patients about breast cancer clinical trials and matches them with appropriate trials.
- Dr. Bonnie Yankaskas, Northern California Cancer Center: The Carolina Mammography Registry is a population-based mammography registry and a member site of the National Cancer Institute Breast Cancer Surveillance Consortium, a registry that provides a resource to study mammography screening on a national level.
- Dr. Carrie Hruska, Mayo Clinic: Molecular Breast Imaging (MBI) is an imaging technique that has greater detection sensitivity than mammography in women with dense breast tissue and is more cost-effective than magnetic resonance imaging (MRI); FDA-approved MBI units are now commercially available.
Gulf War Illness Research Program
- Dr. Beatrice Golomb, University of California San Diego: Administered ill Gulf War Veterans with the antioxidant Coenzyme Q10 to improve chronic Gulf War Illness symptoms such as muscle pain and fatigue, as well as the overall quality of life. This study found significant improvements in reported pain following exertion in Veterans taking 100mg of Coenzyme Q10 twice a day.
Ovarian Cancer Research Program
- Dr. Igor Jurisica, University Health Network University of Toronto: OPHID (http://ophid.utoronto.ca/ophidv2.204/) is a web-based database having over 16 million bits of data to predict interactions between human proteins, and NAViGaToris a companion system for visualizing and analyzing protein-protein interaction networks.
- Dr. Mary Daly, Fox Chase Cancer Center: Developed the first resource book providing information for women considering prophylactic oophorectomy for ovarian cancer prevention and established a high-risk familial breast cancer registry that led to a family risk assessment program.
- Dr. David Bowtell, Peter MacCallum Cancer Centre: Discovered that the Asn372His genotype of BRCA2 significantly increases the risk of ovarian cancer.
Peer Reviewed Medical Research Program
- Dr. Babs Soller, University of Massachusetts Medical School: Developed CareGuideTM, a portable sensor system that noninvasively measures muscle pH, muscle oxygen, and hematocrit from light reflected on the forearm to assess tissue perfusion and guide treatment during resuscitation care.
- Dr. James Childs, Palomar Medical Technologies, Inc.: Developed a hand-held device with a 1,060-nm diode laser and demonstrated safety and efficacy in the treatment of pseudofolliculitis barbae in a 20-subject clinical trial.
- Dr. David Sahn, Oregon Health & Science University: Ultrasound and telemedicine technologies were combined to create a method for the reliable and rapid assessment of newborn infants at risk for heart disease at remote healthcare facilities via telediagnosis. The system allows geographically distant cardiology specialists to supervise real time cardiac ultrasounds performed by physicians and nurses trained to operate a small, hand-held ultrasound device.
Prostate Cancer Research Program
- Dr. Cynthia Menard, University Health Network, Toronto: Designed an advanced customized prostate examination and treatment table for use in a doctor's office to allow better access to the prostate.
- Dr. Martin Pomper, Johns Hopkins University: Produced drugs that attach to prostate tumors and make them more visible in imaging scans.
- The Prostate Cancer Clinical Trials Consortium (PCCTC), Coordinating Center Principal Investigator, Dr. Howard Scher, Memorial Sloan-Kettering Cancer Center: MDV3100, blocks androgen production and improves currently available treatments, has completed Phase III trials and will file in 2012 for FDA approval for castration-resistant prostate cancer. The PCCTC has conducted the rapid clinical testing of the drug.
